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Purpose
To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC)
patients treated with concurrent chemoradiation.
Materials and Methods
From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation
for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative
gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of
American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemo-
therapy was administered every week concurrently with radiation using one of the following
regimens: paclitaxel (60 mg/m
2), docetaxel+cisplatin (20 mg/m
2+20 mg/m
2), cisplatin (30 mg/m
2).
Total radiation dose was 16-66.4 Gy (median, 59.4 Gy).
Results
Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23
complete responses. The median survival duration for the overall patient group was 17.6
months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at
the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis
of the overall patient group, a clinical tumor response (p=0.002) was the only significant pro-
gnostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation
arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10(p=0.007),
and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median
survival duration of the locally recurrent group and the postoperative gross residual group
were 26.4 and 23.9 months, respectively. 
Conclusion
Our study demonstrated that clinical tumor response was significantly associated with OS in
the overall patient group. Further investigations regarding the optimal radiation dose in the
definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC
would be required.
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Introduction
Despite continuous progress in cancer treatment, lung cancer
remains the most common cause of cancer-related deaths in Korea
[1] as well as worldwide [2]. Although the overall survival (OS) rate
has gradually improved, lung cancer still has a high mortality rate
because local and distant failures are common. 
Non-small cell lung cancer (NSCLC) is a heterogeneous group of
diseases that accounts for about 80% of lung cancer cases. Although
surgery can be curative at the early stages of NSCLC, the majority
of patients with NSCLC may already be in a locally advanced stage
that is not amenable to curative resection at diagnosis. 
Historically, thoracic radiotherapy has played a major role in the
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management of locally advanced NSCLC, and many prospective
clinical trials [3-5] have established the benefits of incorporating
chemotherapy with radiotherapy over radiotherapy alone. In recent
years, the improvement in survival rates has been attributed to the
development of modern chemotherapeutic agents and advances in
radiation therapy techniques which improved local tumor control
without significantly increasing radiation-related morbidity. However,
OS and prognosis are still poor in locally advanced NSCLC. There
are some variations in the standard of care for patients with locally
advanced disease. While surgery can be the treatment of choice for
selected N2 positive patients, a neoadjuvant treatment scheme [6]
may be used for potentially resectable diseases. Definitive chemo-
radiation [7,8] may be standard for patients with locally advanced
inoperable NSCLC. Other treatment options, such as induction
chemotherapy followed by chemoradiation [9], chemoradiation
followed by consolidation chemotherapy [10,11] or preoperative
chemoradiation followed by surgery [6,12] can be used, but outcomes
have not been established. 
There are frequently encountered problems such as gross residual
diseases after surgical resection, especially in stage III patients, or
locally recurrent disease. In patients with a good performance status,
aggressive treatment, such as concurrent chemoradiation, could be
helpful because we can eradicate residual disease more effectively
after incomplete surgery. Some reports have shown that the survival of
patients with locally recurrent NSCLC is comparable to that of patients
initially diagnosed with locally advanced NSCLC [13]. Furthermore,
there has been a study reporting that patients with locally recurrent
NSCLC who were treated with curative intent survived much longer
than those who were treated with palliative intent [14,15].
In the current study, we retrospectively analyzed treatment results,
clinical responses, toxicities, and prognostic factors associated with
the OS of patients who received concurrent chemoradiation for
locally advanced stage III NSCLC, postoperative gross residual
diseases, and locally recurrent NSCLC. 
Materials and Methods 
1 Patients
Between January 2005 and June 2009, the Seoul St. Mary’s
Hospital Lung Cancer Multidisciplinary Treatment Team enrolled
55 patients who were histologically confirmed as having NSCLC.
This included locally advanced stage III NSCLC, postoperative
gross residual diseases, and locally recurrent NSCLC. Among these
55 patients, we excluded 4 who had not reached the time of clinical
response evaluation. All patients had pathologically confirmed
measurable disease, an Eastern Cooperative Oncology Group
performance status (ECOG PS) of 0-2, and acceptable pulmonary,
bone marrow, liver and renal functions. For stage evaluation, patients
underwent a chest X-ray, computed tomography (CT) scans of the
chest including upper abdomen, bronchoscopy, and positron emission
tomography/computed tomography (PET/CT). Tc-99m whole body
bone scans, whole abdominal CT scans, and magnetic resonance
imaging of the brain were selectively performed when clinically
indicated. Mediastinoscopy was not routinely done; it was performed
in 6 of 28 patients in the definitive chemoradiation group to dis-
criminate between N2 and N3 diseases. 
2 Treatment 
All patients underwent CT simulation for three-dimensional conf-
ormal radiotherapy planning, and radiation was delivered with 6
MV to 15 MV of photon beam energy by linac-based radiation
units. We used a radiation therapy planning system (Pinnacle ver.
7.6, ADAC Laboratories, Milpitas, CA) for treatment planning. The
total radiation dose was 16-66.4 Gy (median, 59.4 Gy), and the frac-
tional size of 1.8 or 2 Gy was prescribed 5 times a week. The gross
tumor volume (GTV) was defined as the primary tumor mass plus
the involved lymph nodes. The clinical target volume (CTV) was de-
fined as the GTV plus a 3-D expansion of 0.5-1 cm including the ip-
silateral hilum. The planning target volume (PTV) was defined as
the CTV plus a 1 cm expansion circumferentially and a 1-2 cm ex-
pansion in the superior-inferior directions. We did not treat elective
lymph node stations. The entire PTV was encompassed within the
90-95% isodose surface. Dose limits for normal tissue were as
follows: spinal cord received 45-49 Gy (at any point), the lung
volume received 20 Gy (V20) 25-30%, and a mean lung dose
(MLD) 18-20 Gy. Beam arrangement was planned to minimize the
irradiated lung volume usually using 3 to 5 coplanar oblique beams.
Some patients having a bulky tumor were treated with an
anteroposterior-posteroanterior field to include the CTV for the first
30-40 Gy, followed by off-cord oblique beams usually composed of
3-5 beams. Boost field to GTV with reduced margin was routinely
used after 46-50 Gy. Chemotherapy was administered weekly using
one of the following regimens: cisplatin (30 mg/m
2), paclitaxel (60
mg/m
2), docetaxel (20 mg/m
2) plus cisplatin (20 mg/m
2). When hema-
tologic toxicity was severe during treatment, chemotherapy admi-
nistration was delayed based on the medical oncologist’s decision. 
Consolidation chemotherapy was administered 4 weeks after the
finish of the chemoradiation course by the following regimens: 2-4
cycles of docetaxel and cisplatin in 8 patients, 4 cycles of paclitaxel
and cisplatin in 4 patients, and 1 cycle of gemcitabine and carbo-
platin in 1 patient. 
3 Assessment of clinical response and toxicity
Blood chemistry and a complete blood count were obtained weekly,
or more frequently, if needed during the treatment periods. We per-
formed chest CT and/or PET/CT for the evaluation of treatment res-
ponses between 4 and 12 weeks after the end of the chemoradiationCancer Res Treat. 2011;43(1):32-41
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treatment course. The World Health Organization (WHO) criteria
were used for response evaluations. These consisted of complete
response (CR), partial response (PR), stable disease (SD) or progre-
ssive disease (PD). Acute toxicity was assessed using the National
Cancer Institute common toxicity criteria (NCI CTCAE) ver. 3.
4 Statistical analysis
OS was defined as the time from the histologically confirmed
date to the date of death or to the patient’s last visit. Progression free
survival (PFS) was defined as the time from the histologically con-
firmed date to the date of disease progression or the date of the
patient’s last visit. In case of locally recurrent disease, a starting
point for the calculation of OS or PFS was the date on which recur-
rence was confirmed by serial radiologic findings, or histologically if
specimens were available. For statistical analysis, SPSS ver.12.0
(SPSS Inc., Chicago, IL) was used. Kaplan-Meier methods were
used to calculate OS and PFS. A log-rank test was used to compare
survival differences between treatment groups, and the Cox pro-
portional hazards regression model was used to identify independent
prognostic factors and to determine the impact of factors on OS. All
Characteristics No. of patients (%)
Age Median (range, yr) 63 (40-79)
Gender Male 42 (82.4)
Female 9 (17.6)
ECOG PS 0 20 (39.2)
1 27 (53.0)
2 4 (7.8)
Histology Squamous cell carcinoma 28 (54.9)
Adenocarcinoma 17 (33.3)
Others 6 (11.8)
RT indication Definitive 28 (54.9)
PostOP 11 (21.6)
Recurrent 12 (23.5)
Initial staging modality CT 11 (21.6)
CT+PET/CT 34 (66.7)
CT+PET/CT+Mediastinoscopy 6 (11.8)
T stage 0 1 (2)
1 4 (7.8)
2 18 (35.3)
3 10 (19.6)
4 18 (35.3)
N stage 0 7 (13.7)
1 3 (5.9)
2 22 (43.1)
3 19 (37.3)
Clinical stage IIIA 19 (37.3)
IIIB 29 (56.9)
Others 3 (5.9)
Chemotherapy regimen Paclitaxel 24 (47.1)
DP 18 (35.3)
Cisplatin 9 (17.6)
RT dose (BED10)    BED10 70 17 (33.3)
BED10 70 34 (66.7)
Dose/Fraction 180 cGy 32 (62.7)
200 cGy 19 (37.3)
Total RT dose (range, Gy) Definitive arm 59.4 (16-66)
Postoperative arm 47.6 (52.2-59.4)
Recurrent arm 59.4 (46.8-66)
Table 1. Patient, tumor and treatment characteristics in the overall patient group
ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiation therapy; PostOP, postoperative gross residual; CT, computed tomography; PET, positron
emission tomography; DP, docetaxel+cisplatin; BED10, calculated biologically equivalent dose using an   / ratio of 10.Dong-Soo Lee, et al_Concurrent Chemoradiation for Non-small Cell Lung Cancer
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p-values were calculated based on a two-sided test. 
Results
1 Patient characteristics
The number of patients in each treatment group was as follows:
28 in locally advanced stage III NSCLC, 11 in postoperative gross
residual disease, and 12 in locally recurrent NSCLC. Patient cha-
racteristics are shown in Table 1. The median age was 63 years
(range, 40 to 79 years), and 82.4% of patients were male. The
majority of patients had an ECOG PS score of 0-1 (92.1%), and the
distribution of histology findings were squamous cell carcinoma
(54.9%) and adenocarcinoma (33.3%). Stage was determined by the
6th edition of the American Joint Committee on Cancer (AJCC)
staging system. If pathologic specimens were available, we used
pathologic stages for tumor-node-metastasis (TNM) staging. The
distribution of clinical stages was as follows: IIIA (37.3%), IIIB
(56.9%). 
2 Treatment compliance 
Four patients were treated with radiation doses of less than 50 Gy,
which was inappropriate for achieving an optimal radiation effect. In
one patient, treatment was discontinued after 16 Gy of radiotherapy
because acute dyspnea developed after 2 cycles of concurrent
chemoradiation. These symptoms were probably due to a hyper-
sensitivity reaction to the chemotherapeutic agent. In another patient,
treatment was discontinued after 42 Gy of radiotherapy because
abrupt pneumothorax developed during treatment. In the remaining 2
patients, treatment-related toxicities were not severe, but the treatment
was discontinued after their respective radiation doses of 32.4 Gy
and 46.8 Gy by patient decision because of poor general conditions
or other reasons. The median number of chemotherapy cycles during
the concurrent chemoradiation treatment was 6 (range, 2-8). Forty-
five patients (88.2%) were treated with at least 6 cycles of chemo-
therapy. 
3 Clinical response to treatment
Response evaluation was done by chest CT with or without
PET/CT. The number of patients with a response evaluation at 1
month after the end of chemoradiation was 8. The other patients
were evaluated at 3 months after the end of chemoradiation. The
overall response rate (CR+PR) was 84.3% (n=43), including 23 CR
(45.1%). Clinical response in each treatment group is described in
Table 2. The postoperative gross residual group showed a relatively
high CR rate (81.8%), probably due to the reduced tumor burden
after surgical resection. There was no difference in the overall res-
ponse rates among different chemotherapeutic regimens (p=0.194).
4 Patterns of failure after treatment
At the time of this analysis, recurrence has been observed in 21
patients (41%). The distribution of the first site of recurrence is shown
in Fig. 1. Tumors recurred in the following sites: locoregional sites
(23.6%) and distant organs (27.5%). The most common site of distant
metastasis was the brain followed by skeletal system. All of the
patients with recurrent disease received palliative treatments including
chemotherapy, molecular targeted therapy or localized radiotherapy. 
5 Progression-free survival and overall survival
The median follow-up duration in the entire population was 40.8
months (range, 3 to 69.9 months). The median PFS in the entire
population was 12.5 months, and the 1-year and 2-year PFS rates
were 51% and 23%, respectively. There was no statistically
significant difference between treatment groups (p=0.583) (Figs. 2
and 3). The median OS in the entire population  was 17.6 months,
and the 2-year and 3-year OS rates were 42% and 17.8%,
respectively. Median survival was different between treatment
groups but not statistically significant (p=0.638) (Figs. 2 and 3). 
6 Prognostic factors affecting overall survival 
The results of univariate and multivariate analysis affecting OS in
the entire population are shown in Table 3. The covariables were
Clinical response
Responder (%) Non-responder (%) Median survival (mo)
CR PR SD PD Responder Non-responder
Overall  23 (45.1) 20 (39.2) 6 (11.8) 2 (3.9) p=0.054
a) 23.9 8.4 
Definitive  7 (25) 15 (53.6) 4 (14.3) 2 (7.1) 14.6  5.4 
Postoperative  9 (81.8) 1 (9.1) 1 (9.1) 23.9  10.6 
Recurrent 7  (58) 4  (33.3) 1  (8.3) 26.4  8.4 
Table 2. Clinical response rate in the overall patient and each treatment arms
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
a)Chi-square test.Cancer Res Treat. 2011;43(1):32-41
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gender, age, histologic type, ECOG PS score, number of chemo-
therapeutic agents, chemotherapeutic regimen, clinical tumor response,
T stage, N stage, clinical stage and tumor size. In the univariate
analysis, a better ECOG PS score (0 vs. 1-2, p=0.042) and higher
clinical tumor response (CR+PR vs. SD+PD, p=0.002) were signi-
ficantly associated with improved OS, and a trend was detected that
patients with 65 years had better survival than those with 65 years
(p=0.062). Among these factors, clinical tumor response (p=0.002)
was the only independent factor associated with improved OS in  the
multivariate analysis. Kaplan-Meier OS curves stratified by clinical
tumor response in the overall patients group is shown in Fig. 4. 
We performed subgroup analysis of the definitive chemoradiation
arm to evaluate prognostic factors. This analysis included age,
gender, histologic type, ECOG PS score, number of chemotherapeutic
agents, chemotherapeutic regimen, T stage, N stage, clinical stage,
tumor size, use of consolidation chemotherapy, total radiation dose,
Local
Regional Distant
4 (7.8%)
1 (2%)
6 (11.8%)
8 (15.7%) 1 (2%)
Fig. 1. First site of recurrence. The patterns of failure were loco-
regional relapse in 6 (11.8%) patients, distant metastasis in 8
(15.7%) patients, and combined loco-regional and distant failure in
6 (11.8%) patients.
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Fig. 2. Overall survival (A) and progression free survival (B) curves for the overall patient group. The 2-yr and 3-yr overall survival rates were
42% and 17.8%, respectively. The 1-yr and 2-yr progression free survival rates were 51% and 23%, respectively.
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Fig. 3. Overall survival (A) and progression free survival (B) curves according to the treatment arms. There was no statistical difference between
the treatment groups with regard to overall survival (p=0.6389) and progression-free survival (p=0.5833).Dong-Soo Lee, et al_Concurrent Chemoradiation for Non-small Cell Lung Cancer
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which was converted into biologically equivalent dose (BED), and
clinical tumor response. Among these factors, the use of consoli-
dation chemotherapy (p=0.042), BED10 70 (p=0.011) and higher
clinical response (p=0.0049) were significantly associated with
improved OS in the univariate analysis. 
In the multivariate analysis, the use of consolidation chemotherapy
(p=0.022), BED10 70 (p=0.007), and higher clinical tumor response
(p=0.030) were the independent prognostic factors associated with
improved OS. The Results of univariate and multivariate analyses of
the definitive chemoradiation arm are shown in Table 4 and Kaplan-
Meier OS curves stratified by clinical tumor response, BED10 and
use of consolidation chemotherapy are shown in Fig. 5.
7 Toxicity
Hematologic and esophageal toxicity were major acute toxicities.
The incidence of neutropenia ( grade 3) and esophagitis ( grade
3) were 31.4% and 27.5%, respectively. Radiation pneumonitis ( 
grade 3) occurred in 2 patients. MLD of these two patients was 8.8
Gy and 14.8 Gy, respectively. The volume of lung that received 
20 Gy (V20) were 31% and 41%, and 30 Gy (V30) were 24% and
32%, respectively. There were 2 toxic deaths associated with acute
radiation pneumonitis. One death was caused by viral pneumonia
superimposed on acute radiation pneumonitis during hospitalization
around 1 month after the end of the treatment. Another patient died of
acute respiratory distress syndrome during hospitalization 3 months
after the end of treatment. Acute toxicities of the treatment are listed
in Table 5. Chronic esophageal toxicities were observed in 2
patients who presented with esophageal stricture and fistula,
respectively. 
Discussion 
Before the 1990s, locally advanced NSCLC was treated with
radiation alone. After many randomized trials revealed that the
integration of systemic chemotherapy with radiotherapy would be
more beneficial than radiotherapy alone [3-5], combination chemo-
radiation, especially concurrent chemoradiation rather than sequential
chemoradiation [8,16,17], has become one of the standard treatments.
Recently, the Intergroup 0139 [12] study showed improved survival
with preoperative chemoradiation followed by surgery over definitive
chemoradiation in IIIA-N2 NSCLC when lobectomy was possible.
This neoadjuvant chemoradiation protocol can be used to treat
0.0
1.0
Survival
rate
(mo)
0.0
48.0 36.0 24.0 12.0
0.8
0.6
0.4
0.2
60.0 72.0
CR+PR
SD+PD
Fig. 4. Overall survival curves stratified by clinical tumor response
for the total patient group. Overall survival rate between responder
(complete response+partial response [CR+PR]) and non-responder
(stable disease+progressive disease [SD+PD]) groups was statisti-
cally different on log-rank test (p=0.002).
Factor Univariate Multivariate HR (95%CI)
Gender (male vs. female) 0.5261
Age ( 65 yr vs. 65 yr) 0.062 0.104
Histology (SQ vs. adenocarcinoma) 0.5604
ECOG PS (0 vs. 1-2) 0.042 0.118
Chemotherapy regimen (paclitaxel vs. DP vs. Cisplatin) 0.4349
Chemotherapy regimen (taxane vs. non-taxane) 0.5712
No. of chemotherapy regimen (single vs. doublet) 0.6752
Clinical response (CR+PR vs. SD+PD) 0.002 0.002 3.668 (1.591-8.458)
T stage (0-4) 0.9043
N stage (0-3) 0.7905
Clinical stage (IIIA vs. IIIB) 0.5466
Tumor size ( 3 cm vs. 3 cm) 0.8632
Tumor size ( 5 cm vs. 5 cm)  0.6287
Table 3. Univariate and multivariate analysis for the overall patient group
HR, hazard ratio; CI, confidence interval; SQ, squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; DP, docetaxel+cisplatin; CR,
complete response; PR, partial response; SD, stable disease; PD, progressive disease.Cancer Res Treat. 2011;43(1):32-41
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Factor Univariate Multivariate HR (95%CI)
Gender (male vs. female) 0.676
Age ( 65 yr vs. 65 yr) 0.337
Histology (SQ vs. adenocarcinoma) 0.163
ECOG PS (0 vs. 1-2) 0.856
Chemotherapy (taxane vs. non-taxane) 0.179
Consolidation chemotherapy (yes vs. no) 0.042 0.022 3.559 (1.200-10.555)
BED10 (BED10 70 vs. BED10  70) 0.011 0.007 6.184 (1.644-23.259)
Clinical response (CR+PR vs. SD+PD) 0.049 0.030 3.232 (1.123-9.303)
T stage (0-4) 0.769
N stage (0-3) 0.444
Clinical stage (IIIA vs. IIIB) 0.710
Tumor size ( 3 cm vs. 3 cm) 0.837
Tumor size ( 5 cm vs. 5 cm) 0.911
Table 4. Univariate and multivariate analysis of the definitive arm
HR, hazard ratio; CI, confidence interval; SQ, squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; BED10, calculated biologically
equivalent dose using   /  ratio of 10; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
0.0
1.0
Survival
rate
(mo)
0.0
48.0 36.0 24.0 12.0
0.8
0.6
0.4
0.2
60.0 72.0
CR+PR
SD+PD
A
Clinical tumor response
0.0
1.0
Survival
rate
(mo)
0.0
48.0 36.0 24.0 12.0
0.8
0.6
0.4
0.2
60.0 72.0
B
BED10
0.0
1.0
Survival
rate
(mo)
0.0
48.0 36.0 24.0 12.0
0.8
0.6
0.4
0.2
60.0 72.0
C
Consolidation chemotherapy
BED < 70 10
BED > 70 10
No use
Use
Fig. 5. Overall survival curves stratified by (A) clinical tumor
response, (B) biologically equivalent dose (BED)10, (C) use of
consolidation chemotherapy in the definitive arm. The difference in
overall survival rate between responder (complete response+partial
response [CR+PR]) and non-responder (stable disease+progressive
disease [SD+PD]), BED10 70 and BED10 70, was statistically
different, as was the difference between use of consolidation
chemotherapy and no use of consolidation chemotherapy (p=0.049,
0.011 and 0.042, respectively) on log-rank test for the definitive arm.Dong-Soo Lee, et al_Concurrent Chemoradiation for Non-small Cell Lung Cancer
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selected minimal N2 NSCLC patients who become resectable.
However, additional trials with more population-based studies
would be required to show conclusive results. In the current study,
we analyzed the treatment results of 3 different groups: locally
advanced stage III NSCLC, postoperative gross residual disease,
and locally recurrent NSCLC. The median OS time for all patients
was 17.6 months, and the 2-year and 3-year OS rates were 42% and
17.8%, respectively. Those treatment outcomes are comparable with
previous reports [7-11,18]. Among the different groups, locally
advanced NSCLC (n=28, 54.9%) was the most common. The clinical
development of third generation chemotherapy showed potent
radiosensitization effects, and those chemotherapeutic agents are
commonly used with radiotherapy in the definitive chemoradiation
setting [13,19]. The proportion of patients in our study receiving
combined taxane chemotherapy (paclitaxel or decetaxel) was 82.4%,
which was a very high frequency. However, differences in a number
or regimen of chemotherapeutic agent (single vs. double, taxane vs.
non-taxane, platinum vs. non-platinum) did not affect OS signi-
ficantly (Table 3). Our study showed different median survival
durations between treatment groups: 17.6 months in full analysis
patients, 13.2 months in the definitive chemoradiation group, 26.4
months in the locally recurrent group, and 23.9 months in the posto-
perative gross residual group. In the definitive chemoradiation group,
median OS duration was relatively shorter than that of previously
reported. This was probably due to the fact that most of the patients
enrolled in our study were in stage IIIB (71.4%), and a few of those
patients had shorter follow up periods. We compared the effect of
the total radiation dose on OS between two groups of patients-9
patients who received 66 Gy and another 12 patients who were
treated with 59-60 Gy. However, we found that there was no
significant difference in OS between the two groups. This lack of
significance might be due to the small sample size of the group or
the narrow range of total radiation dose differences between the two
groups. Therefore, re-evaluation with longer follow up of larger
sample sizes will be required for more definitive conclusions. In the
locally recurrent group, we noted reliably longer OS with a non-
inferior outcome when compared with the initially diagnosed locally
advanced NSCLC group. This was supported by the several previous
studies [13,14], which implies that aggressive treatment such as
concurrent chemoradiation or dose escalation radiotherapy would
result in improved survival in locally recurrent cases. Among 12
locally recurrent patients in our study, two had only bronchial stump
recurrence and ten had mediastinal lymph node recurrence with or
without bronchial stump recurrence. There have been a few studies
reporting that bronchial stump recurrence has better prognosis than
cases combined with mediastinal lymph node recurrence or chest wall
invasion. Foo et al. [15] reported that patients treated with radical
intent survived much longer. The median survival was 26 months in
the radical intent group and 10.5 months in the palliative intent
group. Although we included the majority of mediastinal lymph node
recurrences, our patients had relatively long OS durations. Our
concurrent chemoradiation scheme might contribute to this outcome,
and this scheme could be justified for locally recurrent cases,
especially those with mediastinal lymph node recurrences. Further
studies are now required to define the beneficial role of combining
chemotherapy with radiotherapy in loco-regionally recurrent NSCLC.
Treatment toxicity was acceptable when compared with previous
studies of concurrent chemoradiation treatment. However, there
were 2 toxic deaths associated with radiation pneumonitis, 1-3 months
after completion of chemoirradiation in 2 elderly patients, which
suggests that a careful evaluation of pulmonary function and close
follow up will be needed after treatment in an immune-suppressed host. 
In the analysis of prognostic factors, the clinical tumor response
was significantly associated with OS not only in the entire patient
cohort, but also in the definitive chemoradiation group. However,
we could not find any significant factors associated with good res-
ponses such as total radiation dose, chemotherapeutic regimen, TNM
stage or histologic type. From the fact that the reduced tumor burden
after surgery resulted in a relatively high CR rate (81.8%), we can
only infer that the tumor burden (tumor volume) could be a signi-
ficant factor. In our study, the T or N stage was not associated with
the response rate, and this may be due to a small sample size. There
have been significant advances in molecular biology, and these will
help pinpoint the factors associated with responses to therapy.
There are several known pre-treatment prognostic factors asso-
ciated with OS in NSCLC such as weight loss, tumor stage, perfor-
mance status and pulmonary function [20,21]. We couldn’t examine
all of these factors due to the limitations of a retrospective study.
However, among the pre-treatment factors, ECOG PS was the most
strongly associated with OS. 
In subgroup analysis of the definitive chemoradiation group, the
use of consolidation chemotherapy, BED10 70, and higher clinical
tumor response were the independent prognostic factors that improved
OS. Furthermore, our subgroup analysis of locally recurrent and
postoperative gross residual diseases indicated that clinical tumor
response and PS are significant prognostic factors affecting OS (data
not shown). This means that more radical tumor control will eventu-
ally be connected to improved survival in NSCLC. 
In the SWOG 9504 [10] trial, concurrent chemoradiation with
etoposide-cisplatin followed by consolidation docetaxel were ad-
ministered to stage IIIB patients. The result was encouraging with a
median survival time of 26 months, and 3-year and 5-year survival
Table 5. Acute toxicity (NCI CTCAE ver. 3 grading system) 
Acute toxicity
No. of patients (%)
Grade 2  Grade 3
Neutropenia 14 (27.5) 16 (31.4)
Thrombocytopenia 5 (9.8) 2 (3.9)
Anemia 6 (11.8) 1 (2.0)
Esophagitis 14 (27.5) 14 (27.5)
Pneumonitis 6 (11.8) 2 (3.9)
NCI CTCAE, National Cancer Institute common toxicity criteria.Cancer Res Treat. 2011;43(1):32-41
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rate were 37% and 29%, respectively. After the SWOG 9504 trial,
several phase III randomized trials [11,22,23] were conducted to
define the role of consolidation chemotherapy in locally advanced
NSCLC. However, different results were shown among the studies,
and some studies showed a relatively high frequency of high-grade
hematologic and esophageal toxicities. In the most recently reported
interim analysis of a multinational phase III randomized trial (CCheIN)
[23], consolidation chemotherapy with docetaxel plus cisplatin (DP)
after concurrent chemoradiation (CCRT) with weekly DP was shown
to be feasible and tolerable, but there were no statistically significant
differences in time to progression and median OS between observation
and consolidation arms. As a result, further investigations are needed
to precisely define the role of consolidation chemotherapy after
CCRT in locally advanced NSCLC. We would cautiously infer that
stage IIIB patients with good PS will benefit mostly from the con-
solidation chemotherapy. In the same context, our study showed that
the benefit of consolidation chemotherapy was probably due to the
high proportion of IIIB patients in the definitive chemoradiation arm.
To further evaluate the radiation dose effect, we calculated BED
using an   / ratio of 10 because the fractional size was different.
However, some patients treated with a less than optimal radiation
dose were included in the study, and we did not apply a time factor
in calculating BED. Thus, a follow up study including a larger cohort
should be performed. In our study, patients treated with BED10 70
showed a better OS when compared to those with BED10 70, and
this was the independent prognostic factor associated with improved
OS in the multivariate analysis (hazard ratio, 6.184; 95% confidence
interval, 1.644 to 23.259; p=0.007). This result needs careful
interpretation: it should be interpreted as the optimal minimum dose
to get the radiation effect attributed to improving overall survival,
not the appropriate radiation dose in the CCRT setting. Many
clinical trials have been performed with a radiation dose of 60-74
Gy [11,23], and the optimal radiation dose in concurrent
chemoradiation setting remains unclear. Although some studies
showed that a higher radiation dose may be correlated with im-
proved local control and OS [24], the results of the ongoing phase
III intergroup study (RTOG 0617) (60 Gy vs. 74 Gy) will more
definitively identify the additional role of a higher radiation dose in
the chemoradiation setting. 
Conclusion
The current study demonstrated that ECOG PS and clinical tumor
response were the independent prognostic factors despite hetero-
geneous composition of the subgroups. In subgroup analysis of the
definitive chemoradiation group, the use of consolidation chemo-
therapy, BED10 70 and higher clinical tumor responses were the
independent prognostic factors correlated with the improved OS. In
locally recurrent NSCLC, our study showed the relatively better OS
outcomes compared with previous studies. However, our study
needs a longer follow up with more population group for more precise
outcomes. Further investigations would be required to define the
factors associated with improving tumor response, the role of
optimal radiation dose in definitive chemoradiation setting, and the
optimal treatment scheme in locally recurrent NSCLC. 
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